zabmedvestnikЗабайкальский медицинский вестникTransbaikalian Medical Bulletin1998-6173Читинская государственная медицинская академия10.52485/19986173_2023_1_122zabmedvestnik-132Research ArticleНАУЧНЫЕ ОБЗОРЫSCIENTIFIC REVIEWSКардиоваскулярные осложнения современных противоопухолевых препаратов (обзор литературы)Cardiovacular toxicity of modern cancer treatment (review)БусыгинВ. В.BusyginV. V.

675000,; ул. Горького, 95; Благовещенск

675000; 95 Gorkogo srt.; Blagoveshchensk

ДаниленкоС. А.DanilenkoS. A.

675000,; ул. Горького, 95; Благовещенск

675000; 95 Gorkogo srt.; Blagoveshchensk

Зайкова-ХелимскаяИ. В.Zaykova-KhelimskayaI. V.

680000; ул. Муравьева-Амурского, д. 35; Хабаровск

680000; 35 Muravyov-Amursky str.; Khabarovsk

Федеральное государственное бюджетное образовательное учреждение высшего образования «Амурская государственная медицинская академия» Министерства здравоохранения Российской ФедерацииРоссияAmur State Medical AcademyRussian FederationФедеральное государственное бюджетное образовательное учреждение высшего образования» Дальневосточный государственный медицинский университет» Министерства здравоохранения Российской ФедерацииРоссияFar Eastern State Medicalь UniversityRussian Federation20230408202401122136Copyright © Бусыгин В.В., Даниленко С.А., Зайкова-Хелимская И.В., 20242024Бусыгин В.В., Даниленко С.А., Зайкова-Хелимская И.В.Busygin V.V., Danilenko S.A., Zaykova-Khelimskaya I.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.zabmedvestnik.ru/jour/article/view/132

   Таргетнаяь терапия современными противоопухолевыми препаратами позволяет значительно улучшить прогноз у пациентов онкологического профиля. Кардиоваскулярные осложения такого лечения могут стать причиной преждевременной отмены лекарственных средств. В статье приводятся данные о наиболее часто встречающихся при применении различных классов противоопухолевых препаратов кардиоваскулярных нежелательных реакций, рассматриваются вопросы их патогенеза и диагностики.

   Targeted therapy with modern cancer treatment can significantly improve the prognosis of survival for patients. Cardiovascular (CV) adverse events (AE) can lead to premature discontinuation of treatment. This article presents data on the most common cardiovascular AEs in the application of various classes of targeting therapy and discusses the issues of pathogenesis and diagnosis CV toxicity.

кардиоваскулярные осложненияпротивоопухолевые препаратынежелательные явленияcardiovascular toxicitycancer treatmentadverse eventsReferencesZamorano J.L., Lancellotti P., Rodriguez Muñoz D., et al.; ESC Scientific Document Group. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J. 2016 Sep 21;37(36):2768-2801. doi: 10.1093/eurheartj/ehw211. Epub 2016 Aug 26. Erratum in: Eur Heart J. 2016 Dec 24.Zamorano J.L., Lancellotti P., Rodriguez Muñoz D., et al.; ESC Scientific Document Group. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J. 2016 Sep 21;37(36):2768-2801. doi: 10.1093/eurheartj/ehw211. Epub 2016 Aug 26. Erratum in: Eur Heart J. 2016 Dec 24.Cancer Therapy Evaluation Program Adverse Event Reporting System [cited 2022 Dec 22]. Available from: https://ctep.cancer.gov/protocolDevelopment/electronic_applications/adverse_events.htmCancer Therapy Evaluation Program Adverse Event Reporting System [cited 2022 Dec 22]. Available from: https://ctep.cancer.gov/protocolDevelopment/electronic_applications/adverse_events.htmВиценя М.В., Агеев Ф.Т., Гиляров М.Ю., Овчинников А.Г., Орлова Р.В., Полтавская М.Г. Практические рекомендации по коррекции кардиоваскулярной токсичности противоопухолевой лекарственной терапии. Злокачественные опухоли : Практические рекомендации RUSSCO #3s2, 2021 (том 11). 41.Vitsenya M.V., Ageev F.T., Gilyarov M.Yu., Ovchinnikov A.G., Orlova R.V., Poltavskaya M.G. Practical recommendations for the correction of cardiovascular toxicity of anticancer drug therapy. Malignant tumors: RUSSCO practice guidelines #3s2, 2021 (Vol. 11). 41. in Russian.Салахутдинова Л.М. Кардиотоксичность при лечении онкологических пациентов (обзор литературы). Поволжский онкологический вестник. 2022. № 2(50). С. 93-110.Salakhutdinova L. M. Cardiotoxicity in the treatment of cancer patients (literature review). Povolzhsky Oncological Bulletin. 2022. No. 2(50). pp. 93-110. in Russian.Liu S., Gao W., Ning Y., Zou X., Zhang W., Zeng L., Liu J. Cardiovascular Toxicity With PD-1/PD-L1 Inhibitors in Cancer Patients: A Systematic Review and Meta-Analysis. Front Immunol. 2022 Jul 8;13:908173. doi: 10.3389/fimmu.2022.908173.Liu S., Gao W., Ning Y., Zou X., Zhang W., Zeng L., Liu J. Cardiovascular Toxicity With PD-1/PD-L1 Inhibitors in Cancer Patients: A Systematic Review and Meta-Analysis. Front Immunol. 2022 Jul 8;13:908173. doi: 10.3389/fimmu.2022.908173.Васюк Ю.А, Шупенина Е.Ю, Новосел Е.О., Агапов И.С. Нарушения ритма и проводимости сердца как проявления кардиотоксичности противоопухолевого лечения - миф или реальность? Сибирский медицинский журнал (г. Томск). 2020. Т. 35. № 1. С. 13-21. DOI: 10.29001/2073-8552-2020-35-1-13-21.Vasyuk Yu.A., Shupenina E.Yu., Novosel E.O., Agapov I.S. Heart rhythm and conduction disturbances as manifestations of cardiotoxicity of anticancer treatment - myth or reality? Siberian Medical Journal (Tomsk). 2020. V. 35. No. 1. S. 13-21. DOI: 10.29001/2073-8552-2020-35-1-13-21. in Russian.Lyon A.R., López-Fernández T., Couch L.S., et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022 Nov 1;43(41):4229-4361. doi: 10.1093/eurheartj/ehac244.Lyon A.R., López-Fernández T., Couch L.S., et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022 Nov 1;43(41):4229-4361. doi: 10.1093/eurheartj/ehac244.Herrmann J., Lenihan D., Armenian S., et al. Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement. Eur Heart J. 2022 Jan 31;43(4):280-299. doi: 10.1093/eurheartj/ehab674.Herrmann J., Lenihan D., Armenian S., et al. Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement. Eur Heart J. 2022 Jan 31;43(4):280-299. doi: 10.1093/eurheartj/ehab674.Перепечко Д.Д. Лекарственно-индуцированная кардиотоксичность, ассоциированная с применением противоопухолевых антибиотиков. Кардиология: новости, мнения, обучение. 2021. Т. 9. № 1(26). С. 32-38. DOI: 10.33029/2309-1908-2021-9-1-32-38.Perepechko D. D. Drug-induced cardiotoxicity associated with the use of antitumor antibiotics. Cardiology: news, opinions, training. 2021. Vol. 9. No. 1(26). pp. 32-38. DOI 10.33029/2309-1908-2021-9-1-32-38. in Russian.Jacobs J.E.J., Guler I., Duchenne J., Janssens S., Van Aelst L.N.L. Predictability of cardiotoxicity: Experience of a Belgian cardio-oncology clinic. Int J Cardiol. 2022 Sep 15;363:119-122. doi: 10.1016/j.ijcard.2022.06.063. Epub 2022 Jun 28.Jacobs J.E.J., Guler I., Duchenne J., Janssens S., Van Aelst L.N.L. Predictability of cardiotoxicity: Experience of a Belgian cardio-oncology clinic. Int J Cardiol. 2022 Sep 15;363:119-122. doi: 10.1016/j.ijcard.2022.06.063. Epub 2022 Jun 28.Desai A., Noor A., Joshi S., Kim A.S. Takotsubo cardiomyopathy in cancer patients. Cardiooncology. 2019 Jul 1;5:7. doi: 10.1186/s40959-019-0042-9.Desai A., Noor A., Joshi S., Kim A.S. Takotsubo cardiomyopathy in cancer patients. Cardiooncology. 2019 Jul 1;5:7. doi: 10.1186/s40959-019-0042-9.Shah C.P., Moreb J.S. Cardiotoxicity due to targeted anticancer agents: a growing challenge. Ther Adv Cardiovasc Dis. 2019 Jan-Dec;13:1753944719843435. doi: 10.1177/1753944719843435.Shah C.P., Moreb J.S. Cardiotoxicity due to targeted anticancer agents: a growing challenge. Ther Adv Cardiovasc Dis. 2019 Jan-Dec;13:1753944719843435. doi: 10.1177/1753944719843435.Nhola L.F., Abdelmoneim S.S., Villarraga H.R., et al. Echocardiographic Assessment for the Detection of Cardiotoxicity Due to Vascular Endothelial Growth Factor Inhibitor Therapy in Metastatic Renal Cell and Colorectal Cancers. J Am Soc Echocardiogr. 2019 Feb;32(2):267-276. doi: 10.1016/j.echo.2018.09.019. Epub 2018 Nov 17.Nhola L.F., Abdelmoneim S.S., Villarraga H.R., et al. Echocardiographic Assessment for the Detection of Cardiotoxicity Due to Vascular Endothelial Growth Factor Inhibitor Therapy in Metastatic Renal Cell and Colorectal Cancers. J Am Soc Echocardiogr. 2019 Feb;32(2):267-276. doi: 10.1016/j.echo.2018.09.019. Epub 2018 Nov 17.Pandey A.K., Singhi E.K., Arroyo J.P., et al. Mechanisms of VEGF (Vascular Endothelial Growth Factor) Inhibitor-Associated Hypertension and Vascular Disease. Hypertension. 2018 Feb;71(2):e1-e8. doi: 10.1161/HYPERTENSIONAHA.117.10271. Epub 2017 Dec 26.Pandey A.K., Singhi E.K., Arroyo J.P., et al. Mechanisms of VEGF (Vascular Endothelial Growth Factor) Inhibitor-Associated Hypertension and Vascular Disease. Hypertension. 2018 Feb;71(2):e1-e8. doi: 10.1161/HYPERTENSIONAHA.117.10271. Epub 2017 Dec 26.Alexandre J., Salem J.E., Moslehi J., et al. Identification of anticancer drugs associated with atrial fibrillation: analysis of the WHO pharmacovigilance database. Eur Heart J Cardiovasc Pharmacother. 2021 Jul 23;7(4):312-320. doi: 10.1093/ehjcvp/pvaa037.Alexandre J., Salem J.E., Moslehi J., et al. Identification of anticancer drugs associated with atrial fibrillation: analysis of the WHO pharmacovigilance database. Eur Heart J Cardiovasc Pharmacother. 2021 Jul 23;7(4):312-320. doi: 10.1093/ehjcvp/pvaa037.McDonagh T.A., Metra M., Adamo M., et al.; ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021 Sep 21;42(36):3599-3726. doi: 10.1093/eurheartj/ehab368. Erratum in: Eur Heart J. 2021 Oct 14.McDonagh T.A., Metra M., Adamo M., et al.; ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021 Sep 21;42(36):3599-3726. doi: 10.1093/eurheartj/ehab368. Erratum in: Eur Heart J. 2021 Oct 14.Williams B., Mancia G., Spiering W., et al; ESC Scientific Document Group. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018 Sep 1;39(33):3021-3104. doi: 10.1093/eurheartj/ehy339. Erratum in: Eur Heart J. 2019 Feb 1;40(5):475.Williams B., Mancia G., Spiering W., et al; ESC Scientific Document Group. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018 Sep 1;39(33):3021-3104. doi: 10.1093/eurheartj/ehy339. Erratum in: Eur Heart J. 2019 Feb 1;40(5):475.Barber M.C., Mauro M.J., Moslehi J. Cardiovascular care of patients with chronic myeloid leukemia (CML) on tyrosine kinase inhibitor (TKI) therapy. Hematology Am Soc Hematol Educ Program. 2017 Dec 8;2017(1):110-114. doi: 10.1182/asheducation-2017.1.110.Barber M.C., Mauro M.J., Moslehi J. Cardiovascular care of patients with chronic myeloid leukemia (CML) on tyrosine kinase inhibitor (TKI) therapy. Hematology Am Soc Hematol Educ Program. 2017 Dec 8;2017(1):110-114. doi: 10.1182/asheducation-2017.1.110.Buza V., Rajagopalan B., Curtis A.B. Cancer Treatment-Induced Arrhythmias: Focus on Chemotherapy and Targeted Therapies. Circ Arrhythm Electrophysiol. 2017 Aug;10(8):e005443. doi: 10.1161/CIRCEP.117.005443.Buza V., Rajagopalan B., Curtis A.B. Cancer Treatment-Induced Arrhythmias: Focus on Chemotherapy and Targeted Therapies. Circ Arrhythm Electrophysiol. 2017 Aug;10(8):e005443. doi: 10.1161/CIRCEP.117.005443.Herrmann J, Yang E.H., Iliescu C.A., et al. Vascular Toxicities of Cancer Therapies: The Old and the New--An Evolving Avenue. Circulation. 2016 Mar 29;133(13):1272-89. doi: 10.1161/CIRCULATIONAHA.115.018347.Herrmann J, Yang E.H., Iliescu C.A., et al. Vascular Toxicities of Cancer Therapies: The Old and the New--An Evolving Avenue. Circulation. 2016 Mar 29;133(13):1272-89. doi: 10.1161/CIRCULATIONAHA.115.018347.Postow M.A., Sidlow R., Hellmann M.D. Immune-Related Adverse Events Associated with Immune Checkpoint Blockade. N Engl J Med. 2018 Jan 11;378(2):158-168. doi: 10.1056/NEJMra1703481.Postow M.A., Sidlow R., Hellmann M.D. Immune-Related Adverse Events Associated with Immune Checkpoint Blockade. N Engl J Med. 2018 Jan 11;378(2):158-168. doi: 10.1056/NEJMra1703481.Drobni Z.D., Alvi R.M., Taron J., et al. Association Between Immune Checkpoint Inhibitors With Cardiovascular Events and Atherosclerotic Plaque. Circulation. 2020 Dec 15;142(24):2299-2311. doi: 10.1161/CIRCULATIONAHA.120.049981. Epub 2020 Oct 2.Drobni Z.D., Alvi R.M., Taron J., et al. Association Between Immune Checkpoint Inhibitors With Cardiovascular Events and Atherosclerotic Plaque. Circulation. 2020 Dec 15;142(24):2299-2311. doi: 10.1161/CIRCULATIONAHA.120.049981. Epub 2020 Oct 2.Rubio-Infante N., Ramírez-Flores Y.A., Castillo E.C., Lozano O., García-Rivas G., Torre-Amione G. Cardiotoxicity associated with immune checkpoint inhibitor therapy: a meta-analysis. Eur J Heart Fail. 2021 Oct;23(10):1739-1747. doi: 10.1002/ejhf.2289. Epub 2021 Jul 29.Rubio-Infante N., Ramírez-Flores Y.A., Castillo E.C., Lozano O., García-Rivas G., Torre-Amione G. Cardiotoxicity associated with immune checkpoint inhibitor therapy: a meta-analysis. Eur J Heart Fail. 2021 Oct;23(10):1739-1747. doi: 10.1002/ejhf.2289. Epub 2021 Jul 29.Dolladille C., Akroun J., Morice P.M., et al. Cardiovascular immunotoxicities associated with immune checkpoint inhibitors: a safety meta-analysis. Eur Heart J. 2021 Dec 21;42(48):4964-4977. doi: 10.1093/eurheartj/ehab618.Dolladille C., Akroun J., Morice P.M., et al. Cardiovascular immunotoxicities associated with immune checkpoint inhibitors: a safety meta-analysis. Eur Heart J. 2021 Dec 21;42(48):4964-4977. doi: 10.1093/eurheartj/ehab618.Lehmann L.H., Cautela J., Palaskas N., et al. Clinical Strategy for the Diagnosis and Treatment of Immune Checkpoint Inhibitor-Associated Myocarditis : A Narrative Review. JAMA Cardiol. 2021 Nov 1;6(11):1329-1337. doi: 10.1001/jamacardio.2021.2241.Lehmann L.H., Cautela J., Palaskas N., et al. Clinical Strategy for the Diagnosis and Treatment of Immune Checkpoint Inhibitor-Associated Myocarditis : A Narrative Review. JAMA Cardiol. 2021 Nov 1;6(11):1329-1337. doi: 10.1001/jamacardio.2021.2241.Awadalla M., Mahmood S.S., Groarke J.D., et al. Global Longitudinal Strain and Cardiac Events in Patients With Immune Checkpoint Inhibitor-Related Myocarditis. J Am Coll Cardiol. 2020 Feb 11;75(5):467-478. doi: 10.1016/j.jacc.2019.11.049.Awadalla M., Mahmood S.S., Groarke J.D., et al. Global Longitudinal Strain and Cardiac Events in Patients With Immune Checkpoint Inhibitor-Related Myocarditis. J Am Coll Cardiol. 2020 Feb 11;75(5):467-478. doi: 10.1016/j.jacc.2019.11.049.Кулиева А.А., Емелина Е.И., Гендлин Г.Е. Сердечно-сосудистые осложнения терапии ингибиторами контрольных точек иммунитета. Качественная клиническая практика. 2019. № 4. С. 55-65. URL: https://cyberleninka.ru/article/n/serdechno-sosudistye-oslozhneniya-terapii-ingibitorami-kontrolnyh-tochek-immuniteta.Kulieva A.A., Emelina E.I., Gendlin G.E. Cardiovascular complications of therapy with immune checkpoint inhibitors. Quality clinical practice. 2019. No. 4. S. 55-65. URL: https://cyberleninka.ru/article/n/serdechno-sosudistye-oslozhneniya-terapii-ingibitorami-kontrolnyh-tochek-immuniteta. in Russian.Salem J.E., Manouchehri A., Bretagne M., et al. Cardiovascular Toxicities Associated With Ibrutinib. J Am Coll Cardiol. 2019 Oct 1;74(13):1667-1678. doi: 10.1016/j.jacc.2019.07.056.Salem J.E., Manouchehri A., Bretagne M., et al. Cardiovascular Toxicities Associated With Ibrutinib. J Am Coll Cardiol. 2019 Oct 1;74(13):1667-1678. doi: 10.1016/j.jacc.2019.07.056.Brown J.R., Byrd J.C., Ghia P., et al. Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients. Haematologica. 2022 Jun 1;107(6):1335-1346. doi: 10.3324/haematol.2021.278901.Brown J.R., Byrd J.C., Ghia P., et al. Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients. Haematologica. 2022 Jun 1;107(6):1335-1346. doi: 10.3324/haematol.2021.278901.Авалян А.А., Саидова М.А., Ощепкова Е.В., Чазова И.Е. Современные подходы к выявлению ранней субклинической кардиотоксичности, индуцированной химиотерапией, у больных раком молочной железы. Евразийский кардиологический журнал. 2018. № 3. С. 50-61.Avalyan A.A., Saidova M.A., Oshchepkova E.V., Chazova I.Ye. Modern approaches to detecting early subclinical cardiotoxicity induced by chemotherapy in patients with breast cancer. Eurasian cardiological journal. 2018, September 20; 3: 56-61. in Russian.Eiger D., Pondé N.F., Agbor-Tarh D., et al. Long-term cardiac outcomes of patients with HER2-positive breast cancer treated in the adjuvant lapatinib and/or trastuzumab Treatment Optimization Trial. Br J Cancer. 2020 May;122(10):1453-1460. doi: 10.1038/s41416-020-0786-x. Epub 2020 Mar 16.Eiger D., Pondé N.F., Agbor-Tarh D., et al. Long-term cardiac outcomes of patients with HER2-positive breast cancer treated in the adjuvant lapatinib and/or trastuzumab Treatment Optimization Trial. Br J Cancer. 2020 May;122(10):1453-1460. doi: 10.1038/s41416-020-0786-x. Epub 2020 Mar 16.Martel S., Maurer C., Lambertini M., Pondé N., De Azambuja E. Breast cancer treatment-induced cardiotoxicity. Expert Opin Drug Saf. 2017 Sep;16(9):1021-1038. doi: 10.1080/14740338.2017.1351541. Epub 2017 Jul 18.Martel S., Maurer C., Lambertini M., Pondé N., De Azambuja E. Breast cancer treatment-induced cardiotoxicity. Expert Opin Drug Saf. 2017 Sep;16(9):1021-1038. doi: 10.1080/14740338.2017.1351541. Epub 2017 Jul 18.Lyon A.R., Dent S., Stanway S., et al. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society. Eur J Heart Fail. 2020 Nov;22(11):1945-1960. doi: 10.1002/ejhf.1920. Epub 2020 Aug 6.Lyon A.R., Dent S., Stanway S., et al. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society. Eur J Heart Fail. 2020 Nov;22(11):1945-1960. doi: 10.1002/ejhf.1920. Epub 2020 Aug 6.Sara J.D., Kaur J., Khodadadi R., et al. 5-fluorouracil and cardiotoxicity : a review. Ther Adv Med Oncol. 2018 Jun 18;10:1758835918780140. doi: 10.1177/1758835918780140.Sara J.D., Kaur J., Khodadadi R., et al. 5-fluorouracil and cardiotoxicity : a review. Ther Adv Med Oncol. 2018 Jun 18;10:1758835918780140. doi: 10.1177/1758835918780140.Čelutkienė J., Pudil R., López-Fernández T., et al. Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the European Society of Cardiology (ESC). Eur J Heart Fail. 2020 Sep;22(9):1504-1524. doi: 10.1002/ejhf.1957. Epub 2020 Aug 21. Erratum in: Eur J Heart Fail. 2021 Feb;23(2):345.Čelutkienė J., Pudil R., López-Fernández T., et al. Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the European Society of Cardiology (ESC). Eur J Heart Fail. 2020 Sep;22(9):1504-1524. doi: 10.1002/ejhf.1957. Epub 2020 Aug 21. Erratum in: Eur J Heart Fail. 2021 Feb;23(2):345.Bhatia N., Santos M., Jones L.W., Beckman J.A., Penson D.F., Morgans A.K., Moslehi J. Cardiovascular Effects of Androgen Deprivation Therapy for the Treatment of Prostate Cancer: ABCDE Steps to Reduce Cardiovascular Disease in Patients With Prostate Cancer. Circulation. 2016 Feb 2;133(5):537-41. doi: 10.1161/CIRCULATIONAHA.115.012519.Bhatia N., Santos M., Jones L.W., Beckman J.A., Penson D.F., Morgans A.K., Moslehi J. Cardiovascular Effects of Androgen Deprivation Therapy for the Treatment of Prostate Cancer: ABCDE Steps to Reduce Cardiovascular Disease in Patients With Prostate Cancer. Circulation. 2016 Feb 2;133(5):537-41. doi: 10.1161/CIRCULATIONAHA.115.012519.Visseren F.L.J., Mach F., Smulders Y.M., et al.; ESC National Cardiac Societies; ESC Scientific Document Group. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021 Sep 7;42(34):3227-3337. doi: 10.1093/eurheartj/ehab484. Erratum in: Eur Heart J. 2022 Nov 7;43(42):4468.Visseren F.L.J., Mach F., Smulders Y.M., et al.; ESC National Cardiac Societies; ESC Scientific Document Group. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021 Sep 7;42(34):3227-3337. doi: 10.1093/eurheartj/ehab484. Erratum in: Eur Heart J. 2022 Nov 7;43(42):4468.Shore N.D., Saad F., Cookson M.S., et al.; HERO Study Investigators. Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer. N Engl J Med. 2020 Jun 4;382(23):2187-2196. doi: 10.1056/NEJMoa2004325. Epub 2020 May 29.Shore N.D., Saad F., Cookson M.S., et al.; HERO Study Investigators. Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer. N Engl J Med. 2020 Jun 4;382(23):2187-2196. doi: 10.1056/NEJMoa2004325. Epub 2020 May 29.Okwuosa T.M., Morgans A., Rhee J.W., et al. American Heart Association Cardio-Oncology Subcommittee of the Council on Clinical Cardiology and the Council on Genomic and Precision Medicine; Council on Arteriosclerosis, Thrombosis and Vascular Biology; and Council on Cardiovascular Radiology and Intervention. Impact of Hormonal Therapies for Treatment of Hormone-Dependent Cancers (Breast and Prostate) on the Cardiovascular System: Effects and Modifications: A Scientific Statement From the American Heart Association. Circ Genom Precis Med. 2021 Jun;14(3):e000082. doi: 10.1161/HCG.0000000000000082. Epub 2021 Apr 26.Okwuosa T.M., Morgans A., Rhee J.W., et al. American Heart Association Cardio-Oncology Subcommittee of the Council on Clinical Cardiology and the Council on Genomic and Precision Medicine; Council on Arteriosclerosis, Thrombosis and Vascular Biology; and Council on Cardiovascular Radiology and Intervention. Impact of Hormonal Therapies for Treatment of Hormone-Dependent Cancers (Breast and Prostate) on the Cardiovascular System: Effects and Modifications: A Scientific Statement From the American Heart Association. Circ Genom Precis Med. 2021 Jun;14(3):e000082. doi: 10.1161/HCG.0000000000000082. Epub 2021 Apr 26.Salem J.E., Waintraub X., Courtillot C., et al. Hypogonadism as a Reversible Cause of Torsades de Pointes in Men. Circulation. 2018 Jul 3;138(1):110-113. doi: 10.1161/CIRCULATIONAHA.118.034282.Salem J.E., Waintraub X., Courtillot C., et al. Hypogonadism as a Reversible Cause of Torsades de Pointes in Men. Circulation. 2018 Jul 3;138(1):110-113. doi: 10.1161/CIRCULATIONAHA.118.034282.

The authors declare that there are no conflicts of interest present.